| Literature DB >> 33930309 |
Silvia Affo1, Ajay Nair2, Francesco Brundu2, Aashreya Ravichandra1, Sonakshi Bhattacharjee1, Michitaka Matsuda3, LiKang Chin4, Aveline Filliol1, Wen Wen1, Xinhua Song5, Aubrianna Decker6, Jeremy Worley2, Jorge Matias Caviglia1, Lexing Yu1, Deqi Yin1, Yoshinobu Saito1, Thomas Savage7, Rebecca G Wells4, Matthias Mack8, Lars Zender9, Nicholas Arpaia10, Helen E Remotti11, Raul Rabadan2, Peter Sims12, Anne-Laure Leblond13, Achim Weber13, Marc-Oliver Riener13, Brent R Stockwell14, Jellert Gaublomme6, Josep M Llovet15, Raghu Kalluri16, George K Michalopoulos17, Ekihiro Seki3, Daniela Sia18, Xin Chen5, Andrea Califano19, Robert F Schwabe20.
Abstract
Cancer-associated fibroblasts (CAF) are a poorly characterized cell population in the context of liver cancer. Our study investigates CAF functions in intrahepatic cholangiocarcinoma (ICC), a highly desmoplastic liver tumor. Genetic tracing, single-cell RNA sequencing, and ligand-receptor analyses uncovered hepatic stellate cells (HSC) as the main source of CAF and HSC-derived CAF as the dominant population interacting with tumor cells. In mice, CAF promotes ICC progression, as revealed by HSC-selective CAF depletion. In patients, a high panCAF signature is associated with decreased survival and increased recurrence. Single-cell RNA sequencing segregates CAF into inflammatory and growth factor-enriched (iCAF) and myofibroblastic (myCAF) subpopulations, displaying distinct ligand-receptor interactions. myCAF-expressed hyaluronan synthase 2, but not type I collagen, promotes ICC. iCAF-expressed hepatocyte growth factor enhances ICC growth via tumor-expressed MET, thus directly linking CAF to tumor cells. In summary, our data demonstrate promotion of desmoplastic ICC growth by therapeutically targetable CAF subtype-specific mediators, but not by type I collagen.Entities:
Keywords: CellPhoneDB; HGF; KRAS; YAP; cholangiocarcinoma; immune; mechanosensitive; single cell; stiffness; tumor microenvironment
Mesh:
Substances:
Year: 2021 PMID: 33930309 PMCID: PMC8241235 DOI: 10.1016/j.ccell.2021.03.012
Source DB: PubMed Journal: Cancer Cell ISSN: 1535-6108 Impact factor: 38.585